How do you assess whether an early-stage Hodgkin's patient is unfavorable?

I personally utilize the GHSG criteria for most patients. To review, a patient has "favorable" disease if they meet all of the following criteria:

1. 1-2 involved sites

2. No bulky disease

3. No extranodal disease (which is rare in early-stage HL)

4. Favorable ESR/B-symptoms profile (ESR < 30 with B symptoms; ESR < 50 without B symptoms)

For early-stage, favorable disease, GHSG trials have demonstrated:

1. 2 cycles of ABVD and 20 Gy of RT provides excellent disease control and more cycles of chemotherapy and/or a higher dose of RT is unnecessary (HD10)

2. ABVD provides the best PFS (compared with AVD, ABV, or AV) (HD13)

3. Dropping the RT after 2 cycles ABVD if the post-chemotherapy PET-CT is negative is associated with inferior PFS (HD16)